Key result
LDL-C target achievement under statin therapy is linked to lower fecal amino acid-related metabolites.
Why the study?
Does achieving an intensive LDL-C target (<70 mg/dL) compared to not achieving the target (≥70 mg/dL) associate with a distinct fecal metabolomic profile in statin-treated adults with chronic diseases?
Cross-Sectional (n=124)
No
Does achieving an intensive LDL-C target (<70 mg/dL) compared to not achieving the target (≥70 mg/dL) associate with a distinct fecal metabolomic profile in statin-treated adults with chronic diseases?
Answers are grounded in this paper and cite their sources.
Achieving an LDL-C target <70 mg/dL on statin therapy is associated with lower fecal levels of eight amino acid metabolites and an Anaerotruncus-linked microbial network, suggesting gut microbial amino acid handling may influence lipid-lowering efficacy.
Whether the fecal metabolome differs according to intensive low-density lipoprotein cholesterol (LDL-C) target achievement among statin-treated patients is unclear. In this cross-sectional study, 124 statin-treated adults with chronic disease were stratified by fasting LDL-C into a target-achieved group (< 70 mg/dL, n=52) and a target-not-achieved group (≥ 70 mg/dL, n=72). Stool samples were profiled by untargeted ultra-high-performance liquid chromatography–tandem mass spectrometry, and multivariable models adjusted for age, sex, chronic kidney disease, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use were used to identify metabolites independently associated with target achievement. Statin dose, treatment duration and glucose-lowering therapy were also compared between the groups. Paired 16S rRNA gene sequencing data available for a subset (n = 86) were used for integrative correlation and network analyses. Partial least-squares discriminant analysis showed separation between the two groups. Eight annotated metabolites—glutamine, glutamate, phenylalanine, N-acetyl-L-phenylalanine, L-methionine, N-acetyl-L-methionine, lysine, and N-methyl-D-aspartic acid, predominantly amino acids and their derivatives—were present at lower fecal levels in participants who achieved the LDL-C target. Metabolite set enrichment analysis implicated amino acid and nitrogen metabolism, and multiomics network analysis identified an Anaerotruncus -centered amino acid module with high degree centrality. In conclusion, LDL-C target achievement under statin therapy was associated with a coherent "low fecal amino acid" signature and an Anaerotruncus -linked microbe–metabolite hub. These findings suggest that intestinal nutrient handling and gut microbial amino acid metabolism may contribute to variability in LDL-C response, and they warrant prospective mechanistic evaluation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cross-sectional in Chronic disease (hypertension, diabetes, or chronic kidney disease) treated with statins (n=124). LDL-C target achievement (<70 mg/dL) on statin therapy vs. LDL-C target not achieved (>=70 mg/dL) on statin therapy was evaluated on Fecal metabolomic profile differences (specifically 8 annotated amino acid-related metabolites) (p=q<0.25). LDL-C target achievement in statin-treated patients was independently associated with lower fecal levels of eight amino acid-related metabolites and an Anaerotruncus-centered network hub.
Synapse has enriched 10 related papers. Consider them for comparative context: